ArticleJACC. CardioOncology2019
The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity.
Article in JACC. CardioOncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Research Priorities and Future Directions in Cardio-Oncology.Current treatment options in oncology · 2026Review
- Circulating Cardiovascular Biomarkers in Cancer Therapeutics-Related Cardiotoxicity: Review of Critical Challenges, Solutions, and Future Directions.Journal of the American Heart Association · 2023Review
- Leveraging Clinical Trial Populations and Data from the Children's Oncology Group for Cancer Survivorship Research.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- The Impact of the Cancer Moonshot on Cardio-Oncology Science.JACC. CardioOncology · 2022Article
- Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.Frontiers in immunology · 2022Review
- Post-Transplantation Cyclophosphamide: An Old Nemesis to a New Transplant Paradigm?JACC. CardioOncology · 2021Article
- Monoclonal Antibody-Based Immunotherapy and Its Role in the Development of Cardiac Toxicity.Cancers · 2020Review
- The cancer patient and cardiology.European journal of heart failure · 2020Review
- Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.Current oncology reports · 2020Review
- Cardiac Imaging in Oncology Patients in Europe: a Model for Advancement of CV Safety and Development of Comprehensive CV Care.Journal of cardiovascular translational research · 2020Review
- Cardio-Oncology and the Patient-Physician Relationship.JACC. CardioOncology · 2020Article
- Birth and Maturation of Cardio-Oncology.JACC. CardioOncology · 2019Article
Corrections and comments
- Commented on by
Authors and funding
15 authors.
Funding
Abstract
Cardiovascular (CV) toxicity from cancer therapy is a significant and growing concern. Conventional oncology clinical trial designs focused singularly on cancer treatment efficacy have not provided sufficient information on both CV risk factors and outcomes. Similarly, traditional CV trials evaluating standard interventions typically exclude cancer patients, particularly those actively receiving cancer therapy. Neither trial type simultaneously evaluates the balance between CV toxicity and cancer outcomes. However, there is increasing collaboration among oncologists and cardiologists to design new cardio-oncology trials that address this important need. In this review, we detail five ongoing, oncology-based trials with integrated CV endpoints. Key design features include: 1) a careful assessment of baseline risk factors for CV disease; 2) an introduction of cardioprotective interventions at various timepoints in cancer therapy; 3) a balance of the risk of subclinical CV injury with the need for ongoing cancer treatment; and 4) an understanding of the time profile for development of clinically apparent CV toxicity. Additional critical priorities in cardio-oncology clinical research include harmonization of data collection and definitions for all physician- and patient-reported exposures and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.